Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764265 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT05764265 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT05764265, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH). The study offered participants who had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive LTP001 (whether they were on LTP001 or not). Unblinding of the treatment received in CLTP001A12201 was generally not needed but could occur on request by the investigator.
Interventions
- DRUG LTP001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-03-27 |
| Est. Completion | 2024-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05764265
The ClinicalTrials.gov registry entry for NCT05764265 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LTP001 is the first listed.
NCT05764265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05764265 about?
NCT05764265 is a clinical study titled "Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants". The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH). The study offered participants who had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive LTP001 (whether they ...
What is the current status of trial NCT05764265?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2023-03-27. Estimated completion is 2024-05-14.
What interventions are being tested in trial NCT05764265?
The interventions under investigation include: LTP001 (DRUG).
Who is sponsoring clinical trial NCT05764265?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.